BioCentury
ARTICLE | Clinical News

SuliXen: Interim Phase I data

June 2, 2008 7:00 AM UTC

Data from four patients in an ongoing, Russian Phase I trial showed that 0.1 and 0.3 IU/kg of SuliXen produced better pharmacodynamic responses, as measured by glucose infusion rate, than 0.2 IU/kg of...